Pancreatic Cancer Research

ResearcherPhilipps University of MarburgActive in the last 2 years

Detlef Klaus Bartsch

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2961-915X; OpenAlex author ID A5089879417. Sources: OpenAlex.

Their work

Papers
48 (first author 5, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
152
Papers, trials and grants by year

2011: 3 papers · 2012: 3 papers · 2013: 6 papers · 2014: 3 papers · 2015: 2 papers · 2016: 2 papers · 2017: none · 2018: 5 papers · 2019: 4 papers · 2020: 2 papers · 2021: 6 papers · 2022: 1 paper · 2023: 5 papers · 2024: 5 papers · 2025: 1 paper

Papers 48

  1. The long non-coding RNA NEAT1 contributes to aberrant STAT3 signaling in pancreatic cancer and is regulated by a metalloprotease-disintegrin ADAM8/miR-181a-5p … Co-author DOI 10.1007/s13402-024-01001-0↗
  2. Pancreatic cancer screening is effective in individuals at risk with predisposing germline gene variants, but not in gene variant-negative familial pancreatic … Last author DOI 10.1002/ueg2.12631↗
  3. A retrospective, multicentric, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients. Co-author DOI 10.1007/s00423-024-03570-y↗
  4. Surgical aspects related to hereditary pancreatic cancer. First author DOI 10.1007/s10689-024-00384-1↗
  5. DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331854↗
  6. Joint Linkage and Association Analysis Using GENEHUNTER-MODSCORE with an Application to Familial Pancreatic Cancer. Co-author DOI 10.1159/000535840↗
  7. Dissecting the role of toll-like receptor 7 in pancreatic cancer. Co-author DOI 10.1002/cam4.5606↗
  8. Characteristics of familial pancreatic cancer families with additional colorectal carcinoma. Last author DOI 10.1007/s10689-023-00328-1↗
  9. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  10. IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. Co-author DOI 10.1136/gutjnl-2022-327855↗
  11. Proteomics biomarker discovery for individualized prevention of familial pancreatic cancer using statistical learning. Co-author DOI 10.1371/journal.pone.0280399↗
  12. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Co-author DOI 10.1053/j.gastro.2021.10.014↗
  13. Postoperative morbidity following pancreatic cancer surgery is significantly associated with worse overall patient survival; systematic review and meta-analysi… Last author DOI 10.1016/j.suronc.2021.101573↗
  14. PRMT1 promotes the tumor suppressor function of p14ARF and is indicative for pancreatic cancer prognosis. Co-author DOI 10.15252/embj.2020106777↗
  15. The German National Case Collection for Familial Pancreatic Carcinoma (FaPaCa)—Knowledge Gained in 20 Years. Co-author DOI 10.3238/arztebl.m2021.0004↗
  16. Extracellular Vesicle-Based Detection of Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.697939↗
  17. Cohort Analysis of ADAM8 Expression in the PDAC Tumor Stroma. Co-author DOI 10.3390/jpm11020113↗
  18. Combinations of Low-Frequency Genetic Variants Might Predispose to Familial Pancreatic Cancer. Last author DOI 10.3390/jpm11070631↗
  19. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Co-author DOI 10.1136/gutjnl-2019-319352↗
  20. Correction: Management of patients with increased risk for familial pancreatic cancer: updated recommendations for the international cancer of the pancreas scr… Co-author DOI 10.1136/gutjnl-2019-319352corr1↗
  21. Progress report: familial pancreatic cancer. First author DOI 10.1007/s10689-019-00125-9↗
  22. Screening of Individuals at High Risk for Pancreatic Cancer First author DOI 10.1016/j.cgh.2019.03.023↗
  23. Reply letter to: "Response to: Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: … Last author DOI 10.1016/j.ijsu.2019.02.017↗
  24. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.7150/thno.29247↗
  25. Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: Systematic review and meta-anal… Last author DOI 10.1016/j.ijsu.2018.09.014↗
  26. Expression of neuropeptide Y and its receptors Y1 and Y2 in pancreatic intraepithelial neoplasia and invasive pancreatic cancer in a transgenic mouse model and… Co-author DOI 10.1016/j.jss.2017.11.010↗
  27. Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic inj… Co-author DOI 10.1038/s41388-017-0100-4↗
  28. German National Case Collection for familial pancreatic Cancer (FaPaCa) - acceptance and psychological aspects of a pancreatic cancer screening program. Last author DOI 10.1186/s13053-018-0100-6↗
  29. The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic Cancer. Co-author DOI 10.3390/jcm7100295↗
  30. Refinement of screening for familial pancreatic cancer. Co-author DOI 10.1136/gutjnl-2015-311098↗
  31. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. Last author DOI 10.1200/jco.2015.64.0730↗
  32. Familial Pancreatic Cancer: To Screen or not to Screen? First author DOI 10.1016/j.ebiom.2015.12.014↗
  33. Limited resection of pancreatic cancer in high-risk patients can result in a second primary. First author DOI 10.1136/gutjnl-2015-309568↗
  34. Familial pancreatic cancer--status quo. Last author DOI 10.1007/s00384-013-1760-3↗
  35. Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pan… Co-author DOI 10.1016/j.neo.2014.05.010↗
  36. MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer. Last author DOI 10.1016/j.tranon.2014.05.007↗
  37. Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1007/s00423-013-1105-2↗
  38. Multiple small "imaging" branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade … Co-author DOI 10.1007/s10689-012-9582-y↗
  39. Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.08.002↗
  40. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Co-author DOI 10.1093/annonc/mdt270↗
  41. Variation in precursor lesions of pancreatic cancer among high-risk groups. Last author DOI 10.1158/1078-0432.ccr-12-2730↗
  42. LCN2 and TIMP1 as Potential Serum Markers for the Early Detection of Familial Pancreatic Cancer. Last author DOI 10.1593/tlo.12373↗
  43. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. Co-author DOI 10.1002/path.3017↗
  44. Familial pancreatic cancer--current knowledge. Co-author DOI 10.1038/nrgastro.2012.111↗
  45. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with r… Co-author DOI 10.1200/jco.2011.38.2960↗
  46. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Last author DOI 10.1007/s10689-010-9414-x↗
  47. Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer. Last author DOI 10.1593/neo.10956↗
  48. Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer. Co-author DOI 10.4161/cbt.11.11.15534↗

Closest collaborators

The 25 strongest of 152 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Emily P. Slater · 21 shared papers, 2011–2024 · strength 2.14
  2. Thomas Mathias Gress · 14 shared papers, 2012–2024 · strength 1.28
  3. Elisabeth Maurer · 5 shared papers, 2018–2024 · strength 1.03
  4. Ioannis Mintziras · 6 shared papers, 2018–2021 · strength 0.77
  5. Konstantin Strauch · 6 shared papers, 2013–2024 · strength 0.68
  6. Matthias Lauth · 6 shared papers, 2013–2025 · strength 0.65
  7. Hans F. A. Vasen · 8 shared papers, 2013–2020 · strength 0.60
  8. Volker Fendrich · 13 shared papers, 2011–2018 · strength 0.60
  9. Peter Langer · 11 shared papers, 2011–2021 · strength 0.53
  10. Malte Buchholz · 4 shared papers, 2013–2025 · strength 0.52
  11. Jörg Walter Bartsch · 3 shared papers, 2021–2025 · strength 0.45
  12. Corinna Ulrike Keber · 3 shared papers, 2021–2024 · strength 0.43
  13. Alfredo Carrato Mena · 5 shared papers, 2016–2022 · strength 0.43
  14. Bettina Lehman · 2 shared papers, 2023–2024 · strength 0.40
  15. Yesim Verel‐Yilmaz · 3 shared papers, 2021 · strength 0.36
  16. Michael B. Ghadimi · 3 shared papers, 2019–2024 · strength 0.33
  17. Waldemar H. Uhl · 3 shared papers, 2019–2024 · strength 0.33
  18. Helmut Friess · 3 shared papers, 2019–2024 · strength 0.33
  19. Christian Alexander Bauer · 3 shared papers, 2018–2023 · strength 0.32
  20. Uta‐Maria Bauer · 2 shared papers, 2021–2025 · strength 0.31
  21. Felix S.R. Picard · 2 shared papers, 2023–2024 · strength 0.29
  22. Anna I. Brichkina · 2 shared papers, 2023–2024 · strength 0.29
  23. Magdalena Huber · 2 shared papers, 2023–2024 · strength 0.29
  24. Veronika Lutz · 2 shared papers, 2023–2024 · strength 0.29
  25. Jens Waldmann · 5 shared papers, 2013–2018 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.